Breast Cancer

Breast Cancer Treatment

Cleveland Clinic's Breast Cancer Program is committed to providing patients with the best possible prevention, detection, and treatment options for breast disease. Breast cancer patients throughout main campus, regional hospitals and family health centers all received standardized care through care path guides and tumor board review. A multidisciplinary team comprising radiologists, pathologists, surgeons, plastic surgeons, medical oncologists, radiation oncologists, nurses, genetic counselors, psychologists, physical therapists, and social workers collaborates with each patient to develop a tailored care plan at National Accreditation Program for Breast Centers accredited sites throughout northeast Ohio.

Five-Year Overall Survival of Female Patients With All Stagesᵃ of Breast Cancer (N= 9920)

2008-2017

ᵃAJCC stage I-IV breast cancer

Five-Year Overall Survival of Female Patients With Breast Cancer by Raceᵃ (N= 9550)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Caucasian (N= 8207) 7923 6938 5952 4458 3135
African-American (N= 1343) 1263 1105 889 694 495

ᵃSelf-Reported

Five-Year Overall Survival of Female Patients With Breast Cancer by Hormone Receptor Status (N= 7888)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Negative (N = 1635) 1535 1281 1039 799 566
ER/PR Positive (N = 6253) 6030 5366 4419 3580 2561

ER= estrogen receptor, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Breast Cancer by HER2 Status (N= 6226)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
HER2 Negative (N = 5154) 4912 4153 3180 2341 1475
HER2 Positive (N = 1072) 1031 889 698 507 324

HER2= human epidermal growth factor receptor 2

Five-Year Overall Survival of Female Patients With Stages I-III Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N= 6348)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Positive (N = 4835) 4710 4169 3412 2742 1942
HER2 Positive (N = 866) 850 740 595 438 288
Triple-Negative (N = 647) 717 574 432 296 182

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stage IV Breast Cancer by Estrogen Receptor, Progesterone Receptor, and HER2 Status (N = 339)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
ER/PR Positive (N = 216) 185 153 103 67 42
HER2 Positive (N = 80) 66 53 28 15 10
Triple Negative (N = 43) 19 9 6 4 3

ER= estrogen receptor, HER2= human epidermal growth factor receptor 2, PR= progesterone receptor

Five-Year Overall Survival of Female Patients With Stageᵃ 0 and I Breast Cancer (N= 5672)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage 0 CC (N = 1670) 1627 1460 1233 973 714
Stage I CC (N = 4002) 3890 3445 2821 2238 1578

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIA and IIB Breast Cancer (N= 2606)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIA (N = 1788) 1717 1505 1228 981 703
Stage IIB (N = 818) 791 677 551 436 290

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Stageᵃ IIIA and IIIB Breast Cancer (N= 703)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIIA (N = 539) 522 438 346 266 184
Stage IIIB (N = 164) 147 122 84 57 40

CC= Cleveland Clinic, NCDB= National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReference group data from the National Cancer Database (Commission on Cancer of the American College of Surgeons and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010.

Five-Year Overall Survival of Female Patients With Late-Stage Breast Cancer (N= 595)

2008-2017

Number at Risk Year 1 Year 2 Year 3 Year 4 Year 5
Stage IIIC (N = 178) 166 132 99 72 55
Stage IV (N = 417) 319 243 156 101 68

CC = Cleveland Clinic, NCDB = National Cancer Database

ᵃAJCC stage I-IV breast cancer

ᵇReferance group data from the National Cancer Database (Commission on Cancer of the American College of Surgeon and the American Cancer Society) 2000-2002, as reported in: Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer Science & Business Media; 2010